Cutaneous T-cell lymphomas may require an exception to the ABHH consensus regarding empiric vancomycin use in febrile neutropenia.
作者信息
Gonzaga Yung, Sanches Jose A
机构信息
National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil; Grupo Oncoclínicas, Rio de Janeiro, RJ, Brazil.
University of Sao Paulo Medical School, SP, Brazil.
出版信息
Hematol Transfus Cell Ther. 2025 May 17;47(3):103844. doi: 10.1016/j.htct.2025.103844.
Abstract
摘要
相似文献
1
Cutaneous T-cell lymphomas may require an exception to the ABHH consensus regarding empiric vancomycin use in febrile neutropenia.皮肤T细胞淋巴瘤可能需要对ABHH关于发热性中性粒细胞减少症经验性使用万古霉素的共识做出例外处理。
Hematol Transfus Cell Ther. 2025 May 17;47(3):103844. doi: 10.1016/j.htct.2025.103844.
2
Pre-emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer.癌症患者中性粒细胞减少伴发热时的抢先性抗真菌治疗与经验性抗真菌治疗。
Cochrane Database Syst Rev. 2022 Nov 28;11(11):CD013604. doi: 10.1002/14651858.CD013604.pub2.
3
Management of febrile neutropenia: consensus of the Brazilian Association of Hematology, Blood Transfusion and Cell Therapy - ABHH.发热性中性粒细胞减少症的管理：巴西血液学、输血与细胞治疗协会（ABHH）共识
Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S346-S361. doi: 10.1016/j.htct.2024.11.119. Epub 2024 Dec 18.
4
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.欧洲癌症研究与治疗组织（EORTC）关于使用粒细胞集落刺激因子降低淋巴瘤和实体瘤成年患者化疗引起的发热性中性粒细胞减少症发生率的指南。
Eur J Cancer. 2006 Oct;42(15):2433-53. doi: 10.1016/j.ejca.2006.05.002. Epub 2006 Jun 5.
5
Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia.用于预防急性淋巴细胞白血病患儿骨髓抑制治疗所致发热性中性粒细胞减少症的集落刺激因子
Cochrane Database Syst Rev. 2005 Jul 20(3):CD004139. doi: 10.1002/14651858.CD004139.pub2.
6
Reducing inappropriate antibiotic use in febrile neutropenia in hematology patients through the implementation of an antibiotic de-escalation protocol.通过实施抗生素降阶梯方案减少血液学患者发热性中性粒细胞减少症中不适当的抗生素使用。
Infect Control Hosp Epidemiol. 2025 May 16;46(7):1-6. doi: 10.1017/ice.2025.90.
7
Decision-tree derivation and external validation of a new clinical decision rule (DISCERN-FN) to predict the risk of severe infection during febrile neutropenia in children treated for cancer.一种用于预测癌症治疗儿童发热性中性粒细胞减少症期间严重感染风险的新临床决策规则（DISCERN-FN）的决策树推导及外部验证
Lancet Child Adolesc Health. 2022 Apr;6(4):260-268. doi: 10.1016/S2352-4642(21)00337-0. Epub 2021 Dec 3.
8
Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.利妥昔单抗治疗后迟发性中性粒细胞减少症：病例系列及文献综述
Medicine (Baltimore). 2010 Sep;89(5):308-318. doi: 10.1097/MD.0b013e3181f2caef.
9
Colony-stimulating factors for chemotherapy-induced febrile neutropenia.用于化疗引起的发热性中性粒细胞减少症的集落刺激因子。
Cochrane Database Syst Rev. 2014 Oct 30;2014(10):CD003039. doi: 10.1002/14651858.CD003039.pub2.
10
Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia.低菌饮食与对照饮食预防化疗导致中性粒细胞减少发作的癌症患者感染的比较
Cochrane Database Syst Rev. 2016 Apr 24;4(4):CD006247. doi: 10.1002/14651858.CD006247.pub3.
本文引用的文献
1
Management of febrile neutropenia: consensus of the Brazilian Association of Hematology, Blood Transfusion and Cell Therapy - ABHH.发热性中性粒细胞减少症的管理：巴西血液学、输血与细胞治疗协会（ABHH）共识
Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S346-S361. doi: 10.1016/j.htct.2024.11.119. Epub 2024 Dec 18.
2
Causes of Death in Cutaneous T-Cell Lymphoma Patients.皮肤 T 细胞淋巴瘤患者的死亡原因。
Dermatology. 2023;239(6):860-867. doi: 10.1159/000531979. Epub 2023 Aug 23.
3
Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock.经验性抗生素治疗方案对伴有感染性休克的中性粒细胞减少症血流感染患者死亡率的影响。
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0174421. doi: 10.1128/AAC.01744-21. Epub 2021 Nov 29.
4
Shock and Early Death in Hematologic Patients with Febrile Neutropenia.发热性中性粒细胞减少症血液学患者的休克和早期死亡。
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01250-19. Print 2019 Nov.
5
Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance.多重耐药时代高危中性粒细胞减少血症合并菌血症患者的不适当经验性抗生素治疗。
Clin Infect Dis. 2020 Mar 3;70(6):1068-1074. doi: 10.1093/cid/ciz319.
6
Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study.蕈样肉芽肿/赛泽里综合征的感染性事件和相关危险因素：一项回顾性队列研究。
Br J Dermatol. 2018 Dec;179(6):1322-1328. doi: 10.1111/bjd.17073. Epub 2018 Oct 12.
7
Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer.针对革兰氏阳性菌的经验性抗生素用于治疗癌症发热性中性粒细胞减少患者。
Cochrane Database Syst Rev. 2017 Jun 3;6(6):CD003914. doi: 10.1002/14651858.CD003914.pub4.
8
Risk Factors for Skin Infections in Mycosis Fungoides.蕈样肉芽肿皮肤感染的危险因素
Dermatology. 2016;232(6):731-737. doi: 10.1159/000455944. Epub 2017 Mar 2.
9
Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome.蕈样肉芽肿和塞扎里综合征患者金黄色葡萄球菌定植的患病率及治疗情况
Br J Dermatol. 2008 Jul;159(1):105-12. doi: 10.1111/j.1365-2133.2008.08612.x. Epub 2008 Jul 1.
10
Infections complicating mycosis fungoides and Sézary syndrome.蕈样肉芽肿和塞扎里综合征的感染并发症。
JAMA. 1992 Mar 11;267(10):1354-8.
Zotero 插件